MX2023013313A - Inhibidores de la psd-95 y usos de los mismos. - Google Patents

Inhibidores de la psd-95 y usos de los mismos.

Info

Publication number
MX2023013313A
MX2023013313A MX2023013313A MX2023013313A MX2023013313A MX 2023013313 A MX2023013313 A MX 2023013313A MX 2023013313 A MX2023013313 A MX 2023013313A MX 2023013313 A MX2023013313 A MX 2023013313A MX 2023013313 A MX2023013313 A MX 2023013313A
Authority
MX
Mexico
Prior art keywords
psd
inhibitors
protein
binding
relates
Prior art date
Application number
MX2023013313A
Other languages
English (en)
Spanish (es)
Inventor
Kristian Strømgaard
Vita Sereikaite
Christian Reinhard Otto Bech-Bartling
Original Assignee
Univ Copenhagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Copenhagen filed Critical Univ Copenhagen
Publication of MX2023013313A publication Critical patent/MX2023013313A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023013313A 2021-05-12 2022-05-12 Inhibidores de la psd-95 y usos de los mismos. MX2023013313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013313A true MX2023013313A (es) 2023-12-04

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013313A MX2023013313A (es) 2021-05-12 2022-05-12 Inhibidores de la psd-95 y usos de los mismos.

Country Status (16)

Country Link
US (1) US20240245793A1 (cg-RX-API-DMAC10.html)
EP (1) EP4337673B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520234A (cg-RX-API-DMAC10.html)
KR (1) KR20240007140A (cg-RX-API-DMAC10.html)
CN (1) CN117295755A (cg-RX-API-DMAC10.html)
AU (1) AU2022274309A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021410A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218073A1 (cg-RX-API-DMAC10.html)
ES (1) ES3040762T3 (cg-RX-API-DMAC10.html)
IL (1) IL307244A (cg-RX-API-DMAC10.html)
MX (1) MX2023013313A (cg-RX-API-DMAC10.html)
PL (1) PL4337673T3 (cg-RX-API-DMAC10.html)
SA (1) SA523451347B1 (cg-RX-API-DMAC10.html)
TW (1) TW202306965A (cg-RX-API-DMAC10.html)
WO (1) WO2022238530A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202308712B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2025009503A1 (ja) * 2023-07-03 2025-01-09 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
WO2025051130A1 (zh) * 2023-09-07 2025-03-13 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD
KR102046830B1 (ko) 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
KR20240007140A (ko) 2024-01-16
IL307244A (en) 2023-11-01
CA3218073A1 (en) 2022-11-17
US20240245793A1 (en) 2024-07-25
TW202306965A (zh) 2023-02-16
BR112023021410A2 (pt) 2023-12-19
AU2022274309A1 (en) 2023-09-28
CN117295755A (zh) 2023-12-26
EP4337673B1 (en) 2025-07-09
SA523451347B1 (ar) 2024-08-27
AU2022274309A9 (en) 2024-01-25
EP4337673A1 (en) 2024-03-20
ZA202308712B (en) 2025-02-26
WO2022238530A1 (en) 2022-11-17
PL4337673T3 (pl) 2026-01-05
ES3040762T3 (en) 2025-11-04
JP2024520234A (ja) 2024-05-23
EP4337673C0 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
ZA202308712B (en) Psd-95 inhibitors and uses thereof
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
MX2025003445A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38)
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
EP4470618A3 (en) Heterocyclic compounds for medical treatment
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
CY1121040T1 (el) Aντιικη θεραπεια
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201891974A1 (ru) Ингибиторы связывания белка wdr5 с белками
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
ATE489088T1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA201991448A1 (ru) Азепановые ингибиторы взаимодействия менин-mll
MX2016006966A (es) Derivados de acidos grasos de inhibidores dimericos de la proteina 95 de la densidad post-sinaptica (psd-95).
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
MX2022015725A (es) Inhibidores peptidicos ciclicos de la proteina 95 de la densidad post-sinaptica (psd-95) y usos de los mismos.
EA201990418A1 (ru) Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat)
EA202091803A1 (ru) Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
EA202192420A1 (ru) Применение онколитических вирусов для лечения рака
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
ZA202305329B (en) Multi-specific antibodies and antibody combinations
MX2024002182A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2021001335A (es) Inhibidores de ckd8/19.